---
document_datetime: 2025-02-04 17:08:25
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cejemly-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: cejemly-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.3541935
conversion_datetime: 2025-12-17 09:43:16.784639
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Cejemly

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0003              | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol | 03/02/2025                          |                                             | SmPC                             |           |
| IB/0002              | C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                      | 11/12/2024                          |                                             | SmPC,                            |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | Veterinary Medicinal Products - Other variation                                                                                                                        |            |     | Labelling and PL   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------|
| IB/0001 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 31/10/2024 | n/a |                    |